Alopecia Areata Registry (NAAR)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00069589 |
Recruitment Status :
Active, not recruiting
First Posted : September 30, 2003
Last Update Posted : May 14, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Alopecia Areata Alopecia Totalis Alopecia Universalis Autoimmune Hair Loss Alopecia Partialis |
Alopecia areata is a condition in which hair is lost either from part of the scalp, all of the scalp, or the entire body, and it affects 1% to 2% of the population. It is thought to be an autoimmune disease and in some cases the disease is hereditary. The Alopecia Areata Registry will collect information and blood samples from clinically well-characterized patients with these three forms of alopecia areata: alopecia partialis (patchy loss of the scalp hair), alopecia totalis (total loss of all scalp hair), and alopecia universalis (complete loss of all hair everywhere on the body). This will be a collection of patients in multi-generational families, twins, single patients with patchy, persistent transient alopecia areata or long-standing alopecia totalis/universalis and with controls (persons unaffected and not related to alopecia patients). Information from these patients will be used to search the human genome for disease-associated loci and/or genes. Researchers interested in doing pathophysiology or treatment studies of this disease will also be able to contact patients having the appropriate form of the disease for the studies in question.
Patients who have been diagnosed with alopecia areata by a dermatologist will be eligible for the registry. Patients will fill out an information form online (alopeciaareataregistry.org). Patients who have a family history or specific types of alopecia will be invited to participate in a more detailed questionnaire and physical exam and have blood samples drawn.
Study Type : | Observational |
Estimated Enrollment : | 3100 participants |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | Alopecia Areata Registry and Immunogenetic Mechanisms |
Study Start Date : | November 2001 |
Estimated Primary Completion Date : | November 2099 |
Estimated Study Completion Date : | November 2099 |

- Alopecia Areata Registry [ Time Frame: Registration on-going ]Database registration of participants via collection of participant epidemiology data.
Biospecimen Retention: Samples With DNA

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Probability Sample |
Patients with alopecia areata (AA), both children and adults, who have been diagnosed by a physician with alopecia universalis, alopecia totalis, patchy persistent AA, or transient mild AA. Family members (related by blood) of these patients, preferably sib-pairs plus parents and multiplex families(persons with at least three family members with AA or alopecia universalis and alopecia totalis).
Also, healthy individuals who are unaffected, non-blood related individuals and do not live in the same household with alopecia areata patient are needed as controls.
Inclusion Criteria
- Diagnosed with alopecia areata by a dermatologist
- United States resident
Accepts Health Volunteers: Non blood-related individuals who are unaffected with alopecia areata and do not live in the same household with alopecia areata patient.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00069589
United States, California | |
University of California, San Francisco | |
San Francisco, California, United States, 94143 | |
United States, Colorado | |
University of Colorado - UCHSC - Health Science Center at Fitzsimons | |
Aurora, Colorado, United States, 80010-7163 | |
United States, Minnesota | |
University of Minnesota | |
Minneapolis, Minnesota, United States, 55455 | |
United States, New York | |
Columbia University | |
New York, New York, United States, 10032 | |
United States, Texas | |
M.D. Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Madeleine Duvic, MD | M.D. Anderson Cancer Center |
Publications of Results:
Responsible Party: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00069589 |
Obsolete Identifiers: | NCT00177073 |
Other Study ID Numbers: |
NIAMS-097 HHSN268200682279C |
First Posted: | September 30, 2003 Key Record Dates |
Last Update Posted: | May 14, 2019 |
Last Verified: | May 2019 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Baldness Autoimmunity Hair Alopecia Areata |
Alopecia Partialis Alopecia Totalis Alopecia Universalis Autoimmune Hair Loss |
Alopecia Alopecia Areata Hypotrichosis |
Hair Diseases Skin Diseases Pathological Conditions, Anatomical |